Pharmacometric and electrocardiographic evaluation of chloroquine and azithromycin in healthy volunteers
Chloroquine and azithromycin were developed in combination for the preventive treatment of malaria in pregnancy, and more recently were proposed as coronavirus disease 2019 (COVID-19) treatment options. Billions of doses of chloroquine have been administered worldwide over the past 70 years but conc...
Main Authors: | Chotsiri, P, Tarning, J, Hoglund, RM, Watson, JA, White, NJ |
---|---|
Format: | Journal article |
Language: | English |
Published: |
American Society for Clinical Pharmacology and Therapeutics
2022
|
Similar Items
-
A pharmacometric approach to evaluate drugs for potential repurposing as COVID-19 therapeutics
by: Wattanakul, T, et al.
Published: (2022) -
Population pharmacokinetics and electrocardiographic effects of dihydroartemisinin-piperaquine in healthy volunteers
by: Chotsiri, P, et al.
Published: (2017) -
Concentration-dependent mortality of chloroquine in overdose
by: Watson, JA, et al.
Published: (2020) -
COVID-19 prevention and treatment: A critical analysis of chloroquine and hydroxychloroquine clinical pharmacology
by: White, NJ, et al.
Published: (2020) -
Primaquine in glucose-6-phosphate dehydrogenase deficiency: an adaptive pharmacometric assessment of ascending dose regimens in healthy volunteers
by: Pukrittayakamee, S, et al.
Published: (2024)